N/A N=10 Exercise-primed Upper Extremity Motor Practice in Chronic Stroke
Stroke
Primary: Change in Upper Extremity Impairment as Assessed by the Fugl-Meyer Assessment - Upper Extremity — 2.6 units on a scale — p=.15
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=1 Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
Relapsed Pediatric ALL · Relapsed Pediatric AML · Refractory Acute Myeloid Leukemia
Primary: Incidence of Low Dose Daunorubicin Feasbility as Assessed by Absolute Blast Count — 0; 1 Participants
Phase 3 N=1 Oral Iron Versus Oral Iron Plus a Web-based Behavioral Intervention in Young Children (IRONCHILD)
Iron Deficiency Anemia · Iron-deficiency
Primary: Percentage of Eligible Patients Enrolled — 1; 0 Participants
Phase 2 N=52 Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
Metastatic Breast Cancer
Primary: Sorafenib in Combination With Fixed Dose of of 2.5mg of Letrozole Maximum Tolerated Dose (MTD) — 400 milligrams twice daily
Phase 2 N=205 A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease
Mucocutaneous Lymph Node Syndrome · Kawasaki Disease
Primary: IVIG Refractory — 13; 22 Participants — p=.10
N/A N=68 Therapist Education and Massage for Parent Infant-Outcomes
Parent-Child Relations · Parents · Extreme Prematurity
Primary: Percent of Eligible Dyads Who Would Consent to Enroll (Recruitment) — 91 percentage of participants
N/A N=50 Accelerated TMS to a Novel Brain Target in MDD and PTSD
Post Traumatic Stress Disorder · Major Depressive Disorder
Primary: Percent Change in Depression Severity of TMS at fMRI-guided Brain Target vs Standard Brain Target — 49.11; 24.94; 36.47; 42.56 percentage of change
N/A N=66 Effect of Vitamin D3 Supplementation on Insulin Resistance- The DIR Study
Sub-optimal Vitamin D Status · Pre-diabetes · Insulin Resistance
Primary: Change in Insulin Resistance — 37.4; 36.3 μmol/kg/min (Step 2 GIR corrected)
N/A N=30 Clinical Performance Evaluation of 3D Ear Canal Scanning Technology
Ear Mold Impression Procedure
Primary: Elapsed Time in Minutes to Complete Bilateral Ear Impressions — 8.15; 6.28 Minutes
Phase 2 N=256 A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
Molluscum Contagiosum
Primary: Proportion of Subjects Achieving Complete Clearance at Week 12 — 5; 16; 13; 18 Participants
Phase 2 N=350 Women's Isoflavone Soy Health (WISH) Trial
Atherosclerosis
Primary: Progression of Subclinical Atherosclerosis — 4.77; 5.68 um/year — p=0.35
Phase 4 N=32 Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection
Hepatitis C, Chronic · Opioid-use Disorder
Primary: Number of Participants Initiating in Hepatitis C Virus (HCV) Treatment — 21 Participants
N/A N=58 Symptom Perception
Asthma
Primary: Asthma Control Questionnaire (ACQ) — 1.2; 1.4; 0.8; 1.4 score on a scale
Phase 2 N=27 Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance
Colic
Primary: The Absolute Differences of I-GERQ-R Total Score at V3 (End of First Week of Treatment) Respect to the Baseline (V2). — -6.8; -7.6; -6.8 score on a scale
Phase 2 N=187 RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
Breast Cancer
Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…